Ariad files FDA application and gets acquired

As of August 30, 2016 Arriad had filed its new drug application with the FDA for brigatinib. As of Oct 31, 2016 the FDA granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017.

As of January 9, 2017 Ariad agreed to be bought by Takeda Pharmaceutical Company Limited, a Japanese company. The merger is expected to close by the end of February 2017.

This entry was posted in brigatinib-Alunbrig from Takeda, Lung cancer, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply